Wolfgang Miesbach: Exceptional Presentation on the Role of vWF in Angiogenesis and Gut Angiodysplasia in VWD
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Outstanding science at EAHAD 2026 in Dublin!
One of the highlights of this year’s congress was the exceptional presentation by Anna Randi on the fascinating — and still underappreciated — role of Von Willebrand Factor in angiogenesis and gut angiodysplasia in VWD, why VWF replacement therapy fails in GI bleeding — and what we can do about it.
The clinical problem: 5–20% of VWD patients suffer recurrent, intractable GI bleeding from angiodysplasia — dilated, fragile mucosal vessels prone to rupture.
VWF/FVIII concentrates reduce joint bleeds effectively, but annualised GI bleed rates remain stubbornly high (median 6 episodes/year even on prophylaxis, VWD-PN data).
Beyond the gut: Vascular abnormalities in VWD are not restricted to the GI tract. A scoping review of 61 studies and 146 patients confirmed malformations also in the mouth and face, skin, spleen, brain (AVMs), and genitourinary tract — with 15 patients documented as having HHT. All subtypes are affected, most frequently type 2A, 2B, and type 3.
The mechanism: VWF is not just a haemostatic protein — it is essential for forming Weibel-Palade Bodies (WPB) in endothelial cells. WPBs store Angiopoietin-2 (Angpt-2); without VWF, Angpt-2 leaks out continuously, disrupting the Angpt-1/Angpt-2 balance at the TIE2 receptor, driving pathological sprouting angiogenesis, vascular permeability, and inflammation.
The evidence: VWF-deficient ECs show increased tube formation, increased migration (reversed by VEGFR-2 inhibitor SU4312), and increased Angpt-2 secretion — confirmed in Matrigel, zebrafish models, and human colon tissue.”

Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 20, 2026, 12:29Thirunavukkarasu Angappan: Antithrombin in ECMO – Two Datasets, Two Opposite Answers
-
Nov 20, 2026, 11:38Muhammad Kashif: Therapeutic Plasma Exchange – Key Concepts at a Glance
-
Nov 20, 2026, 11:33Tyler McConville: Why Hemostatic Function Matters More Than Cell Counts in Trauma and Transfusion
-
Nov 20, 2026, 11:28Stéphanie Forté: Bringing Cutting-Edge Genomic and Proteomic Tools to Sickle Cell Disease Patients
-
Nov 20, 2026, 11:19EHC Urges Equal Early Diagnosis for Bleeding Disorders
-
Nov 20, 2026, 11:14Pushpinder Singh: How Do We Know if Haemodialysis is Effective?
-
Nov 20, 2026, 11:09Neel Patel: Honoured to Serve Across Five Faculty Roles at Hematocon 2026
-
Nov 20, 2026, 11:03Alok Khorana: First FXI Inhibitor Approved in the US
-
Nov 20, 2026, 06:51How YERM Shapes the Careers of Future Hematology Researchers – EHA